According to a recent LinkedIn post from HistoSonics, the company is highlighting a breakfast symposium at the Society of Surgical Oncology (SSO) meeting in Phoenix focused on histotripsy moving from innovation to implementation. The session, featuring surgical oncology experts from MD Anderson Cancer Center at Cooper and Northeast Georgia Medical Center, centers on real-world experience, evidence, and future directions for the technology.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post also notes that HistoSonics representatives will be available at booth 821 to discuss the Edison Histotripsy System, while emphasizing that use outside liver applications remains limited to clinical investigations. For investors, the presence at a major oncology conference and engagement with key opinion leaders may signal efforts to drive clinical adoption, generate supporting data, and position the Edison platform for broader commercialization within regulated indications over time.
Increased visibility among surgical oncologists could help build referral networks and inform future procedural volumes if clinical and regulatory milestones are achieved. However, the regulatory disclaimer in the post underlines that revenue growth prospects are still tied to liver-focused use and the pace at which additional indications progress through clinical trials and approvals.